A stronger 7.2 mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the Commissioner’s National Priority Voucher, shortening standard timelines. STEP ...

Semaglutide went off patent in India on March 20, immediately drawing in generic manufacturers with prices starting as low as ...

The FDA approved the new injectable Wegovy HD, or “higher dose,” which has about three times as much medication per shot as ...

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire ...

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction in the long term. NVO expects to ...

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

The modeled fair value for Hims & Hers Health has been revised from about US$44.36 to around US$23.69, a reset of roughly 47% ...

Gastrointestinal tolerability remained the dominant adverse-reaction cluster, aligning with established GLP‑1 receptor agonist class effects across dose ranges. A higher-dose signal of altered skin ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

Just about 10 weeks after it was approved by the US Food and Drug Administration, the Wegovy pill is now estimated to be part of the daily regimen of about ...